Funding Opportunity: Comprehensive Geriatric Assessment (CGA)

Mixed consortia of robot manufacturers and research institutes have the opportunity to apply for a total funding of 1.2 million Euros in a competitive process in order to develop small-scale test series as solutions for the given challenge. AQuAS (Agència de Qualitat I Avaluació Sanitàries de Catalunya), a public entity of the Catalan Department of Health, and Fundació Privada Sant Antoni Abat, a non-profit private foundation managing and developing innovation and research in healthcare, have defined the Comprehensive Geriatric Assessment (CGA) challenge. This challenge specifies the requirements of the public bodies for a robotic product that is not yet available on the market.

The Comprehensive Geriatric Assessment (CGA) is a diagnostic instrument designed to collect data on the medical, psychosocial and functional resources and problems of elderly patients. The information gathered is used to create a plan for treatment and followup. Currently, CGA is performed by social and clinical professionals involved in the care of elderly people: physiotherapists, occupational therapists, nurses, social workers, psychologists, medical doctors, etc. The goal of utilizing a robot to control and to conduct the geriatric tests is to reduce the amount of time medical professionals spend on taking tests and thereby enable them to invest this time oncare planning decisions. In order to master this challenge, multi-institutional consortia or development teams will need to apply for funding in a competitive process in order to develop prototypes according to the needs of the public bodies.

The aim of ECHORD++ (European Clearing House for Open Robotics Development Plus Plus) is to strengthen the knowledge transfer between scientific research, industry and users in robotics and to stimulate their cooperation. The EU-funded project with a runtime of five years (2013 - 2018) funds small-scale research projects called experiments, Public end-user Driven Technological Innovation (PDTI), and established Robotics Innovation Facilities (RIFs), open labs which provide state-of-the-art robotic hardware and software as well as scientific and technical support. ECHORD++ is a joint project of Technische Universität München (project coordinator), Blue Ocean Robotics, Bristol Robotics Laboratory, Commissariat à l’Énergie Atomique et aux Énergies Alternatives, R.U. Robots, Scuola Superiore Sant’Anna, TechnoDeal and Universitat Politècnica de Catalunya.

The idea behind Public end-user Driven Technological Innovation (PDTI) in ECHORD++ is to include public bodies in the robotic product development. By acting as technologically demanding first buyers, public procurers can drive innovation from the demand side and promote the transfer of robotic technology from research to the market. Since public bodies often have specific requirements for the products they use, ECHORD++ will strive to find the best way to integrate them in the product development process. This is to make sure that the product meets the requirements of the target group, technically and price-wise. Thus, ECHORD++ hopes to close the innovation gap between what is available on the market and the public sector's needs.

Closing date: 23rd June 2015

For further information about PDTI, please visit:
http://www.echord.eu/pdti/

E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel.: +49 89 289 18136

The project ECHORD++ is funded under EU’s Seventh Framework Programme for Research (FP7), Grant Agreement No. 601116.

Most Popular Now

First Therapy Chatbot Trial Shows AI can…

Dartmouth researchers conducted the first clinical trial of a therapy chatbot powered by generative AI and found that the software resulted in significant improvements in participants' symptoms, according to results...

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...

A Novel AI-Based Method Reveals How Cell…

Researchers from Tel Aviv University have developed an innovative method that can help to understand better how cells behave in changing biological environments, such as those found within a cancerous...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...